The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.

ABSTRACT:

Background

Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly reduce disease burden are essential for achieving TB elimination. We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

Methods and findings

We developed a system of epidemiological and economic models, calibrated to demographic, epidemiological, and health service data in 105 LMICs. For each country, we assessed the likely future course of TB-related outcomes under several vaccine introduction scenarios, compared to a "no-new-vaccine" counterfactual. Vaccine scenarios considered 2 v

SUBMITTER: Portnoy A 

PROVIDER: S-EPMC9873163 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature